Finanzen von Protagenic Therapeutics Inc (PTIX)PTIXProtagenic Therapeutics Inc

Protagenic Therapeutics Inc (PTIX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Transactional Services, accounting for 79.8% of total sales, equivalent to $9.83M. Another important revenue stream is Subscriptions. Understanding this composition is critical for investors evaluating how PTIX navigates market cycles within the Biotechnology & Medical Research industry.

In the context of the broader market, PTIX competes directly with industry leaders such as PBM and BDRX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, PTIX's gross margin of N/A stands against PBM's N/A and BDRX's N/A. Such benchmarking helps identify whether Protagenic Therapeutics Inc is trading at a premium or discount relative to its financial performance.